Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Meet The Two Nano-Caps That Are Putting A Charge In The Pharmaceutical Industry Today

Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF) and WaferGen Bio-systems, Inc. (NASDAQ:WGBS) are among the hot stocks of the current trading session, booking gains of 34.52% and 10.96%, respectively. Let’s find out the primary reasons behind the bullish investor activity as well as the hedge fund sentiment surrounding these biopharmaceutical companies.

Most Affordable Medical Schools in Europe

We’ll start with Can Fite Biopharma, which according to a press release from the company, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its drug CF102, for use as a second line treatment for hepatocellular carcinoma, which is the most common form of lung cancer. Fast Track Designation is granted to new medical drugs that answer unmet medical requirements of patients and the approval is likely to speed up the development of CF102, which was already given an Orphan Drug designation by the institution.

Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF)’s treatment is currently in phase 2 testing and the company is likely to complete the patient enrollment process in the first half of 2016. It already received the European Medicines Agency’s approval for dosing patients in its global phase 2 study of CF102 in May of this year. If the company succeeds in its upcoming study and approval phase, it could open a $2 billion market for the company, which is primarily dominated by Nexavar, a drug co-developed and marketed by Bayer AG (ADR) (OTCMKTS:BAYRYand Onyx Pharmaceuticals (NASDAQ:ONXX). Nexavar reported annual sales of $874 million in 2014. Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF) filed its semi-annual report on August 27 for the six months ended on June 30, posting a net loss of $2.19 million and cash assets worth $7.75 million.

Why do we pay attention to hedge fund sentiment? Most investors ignore hedge funds’ moves because as a group their average net returns trailed the market since 2008 by a large margin. Unfortunately, most investors don’t realize that hedge funds are hedged and they also charge an arm and a leg, so they are likely to underperform the market in a bull market. We ignore their short positions and by imitating hedge funds’ stock picks independently, we don’t have to pay them a dime. Our research have shown that hedge funds’ long stock picks generate strong risk adjusted returns. For instance the 15 most popular small-cap stocks outperformed the S&P 500 Index by an average of 95 basis points per month in our back-tests spanning the 1999-2012 period. We have been tracking the performance of these stocks in real-time since the end of August 2012. After all, things change and we need to verify that back-test results aren’t just a statistical fluke. We weren’t proven wrong. These 15 stocks managed to return 118% over the last 36 months and outperformed the S&P 500 Index by 60 percentage points (see the details here).

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.